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Abstract
Background: Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth
factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor b tyrosine kinases.
Methods: In this multicenter phase I dose-escalation study including a phase II like expansion part, 39 patients
with refractory colorectal cancer (CRC) were enrolled into 14 days on / 7 days off in repeating cycles of 28 days
(n = 11) or continuous dosing groups (n = 28) to receive ≥ 600 mg telatinib twice-daily (bid).
Results: Hypertension (28%) and diarrhoea (15%) were the most frequent study drug-related adverse events of CTC
grade 3. In this population, no clear relationship between telatinib dose and individual Cmax and AUC was apparent in
the 600 mg bid to 1500 mg bid dose range. No partial remission according to RECIST was reached, but 41% of the
patients reached some tumour shrinkage during treatment. Tumour blood flow measured by dynamic contrast-
enhanced magnetic resonance imaging and sVEGFR-2 plasma levels decreased with increasing telatinib AUC(0-12).
Conclusion: Telatinib treatment was well tolerated. The observed single agent antitumor activity in heavily
pretreated CRC patients was limited. Pharmacodynamic results are suggestive for the biological activity of telatinib
justifying a further evaluation of telatinib bid in combination with standard chemotherapy regimens in CRC patients.
Background
Telatinib (BAY 57-9352) is an orally available, potent,
small-molecule inhibitor of vascular endothelial growth
factor (VEGF) receptors 2 and 3 (VEGFR-2/-3) and plate-
let-derived growth factor (PDGF) receptor b (PDGFR-b)
tyrosine kinases. The datap r e s e n t e di nt h i sp a p e r
describe the results of colorectal cancer (CRC) patients
from the dose escalation part and the phase II-like expan-
sion part of a phase I dose escalation study in which
patients received telatinib at doses of ≥ 600 mg bid (n =
39). Data from 19 of these 39 CRC patients were pre-
sented earlier [1].
Methods
The study methods, treatment plan, patient evaluation,
pharmacokinetic sampling, and pharmacodynamic
measurements from the phase I dose escalation part of
this study have been previously described [1] and the
study assessments were not changed for the expansion
part.
Results
Patient characteristics
A total of 39 Caucasian CRC patients (adenocarcinoma)
were included into a noncontinuous (n = 11; telatinib
administration 14 days on / 7 days off in repeating cycles
of 28 days) and a continuous treatment group (n = 28;
daily telatinib administration) at dose levels of 600 mg bid
(overall n = 6; continuous n = 1), 900 mg bid (overall n =
6; continuous n = 3), 1200 mg bid (only continuous dosing
n = 2), 1500 mg bid (overall n = 4; continuous n = 1), and
900 mg bid continuous dosing for the patients enrolled in
the phase II-like extension cohort of the study (n = 21).
Patient demographics are summarized in Table 1. The
patients were heavily pretreated, 98% had received any
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(87%), irinotecan (77%), cetuximab (56%), capecitabine
(28%), bevacizumab (15%), and mitomycin (15%).
Safety
The most frequent adverse event assessed by the investi-
gators as study drug related was hypertension (all grades:
36%, grade 3: 28%). In 1 patient at 1500 mg bid noncon-
tinuous dosing group, hypertension resulted in dose
reduction and dose interruption. Other study drug
related adverse events occurring in ≥15% of patients were
diarrhoea (26%, grade 3: 15%), anorexia (26%, only grades
1 - 2), nausea (18%, only grades 1 - 2) and fatigue (15%,
g r a d e3 :3 % ) .G a s t r o i n t e s t i n a l toxicities occurred more
often in the continuous dosing group (Table 2). There
were no study drug-related adverse events of CTC grades
4 or 5 reported. Study drug-related adverse events lead-
ing to a dose reduction or study drug discontinuation
Table 1 Patient demographics
Parameter Non-continuous dosing (n = 11) Continuous dosing (n = 28) Total (n = 39)
Gender (female/male) 5 (45%)/6 (55%) 14 (50%)/14 (50%) 19 (49%)/20 (51%)
Mean age (range) (years) 62.4 (42-80) 59.4 (22-78) 60.2 (22-80)
Mean BMI (range) (kg/m
2) 26.5 (21.9-32.0) 26.0 (18.2-37.4) 26.2 (18.2-37.4)
ECOG PS (0/1) 7 (64%)/4 (36%) 23 (82%)/5 (18%) 30 (77%)/9 (23%)
Prior chemotherapy 10 (91%) 28 (100%) 38 (97%)
Prior radiotherapy 3 (27%) 8 (29%) 11 (28%)
Prior surgery 11 (100%) 27 (96%) 38 (97%)
- BMI - body mass index
- ECOG PS - Eastern Cooperative Oncology Group performance status.
Table 2 Incidence of patients with treatment-emergent, study drug-related adverse events with worst CTC grade (all
grades/grade 3)
NCI CTC term Non-continuous dosing (n = 11) Continuous dosing (n = 28) Total (n = 39)
All Grades Grade 3 All Grades Grade 3 All Grades Grade 3
Hypertension 7 (64%) 6 (55%) 7 (25%) 5 (18%) 14 (36%) 11 (28%)
Diarrhoea (patients with or without colostomy) 10 (36%) 6 (21%) 10 (26%) 6 (15%)
Anorexia 1 (9%) 9 (32%) 10 (26%)
Nausea 1 (9%) 6 (21%) 7 (18%)
Fatigue (lethargy, malaise, asthenia) 2 (18%) 3 (11%) 1 (4%) 6 (15%) 1 (3%)
Flatulence 4 (14%) 4 (10%)
Vomiting 1 (9%) 3 (10%) 4 (10%)
Voice changes/stridor/larynx (hoarseness) 3 (27%) 1 (4%) 4 (10%)
Dizziness/lightheadedness 4 (14%) 4 (10%)
Dyspepsia/heartburn 3 (11%) 3 (8%)
Myalgia (muscle pain) 1 (9%) 2 (7%) 3 (8%)
Weight loss 2 (7%) 2 (5%)
Insomnia 1 (9%) 1 (4%) 2 (5%)
Dehydration 1 (4%) 1 (4%) 1 (3%) 1 (3%)
Hand-foot skin reaction 1 (4%) 1 (4%) 1 (3%) 1 (3%)
Rash/desquamation 1 (4%) 1 (4%) 1 (3%) 1 (3%)
Platelets 1 (4%) 1 (3%)
Palpitations 1 (4%) 1 (3%)
Gastritis 1 (4%) 1 (3%)
Stomatitis/pharyngitis (oral/pharyngeal mucositis) 1 (4%) 1 (3%)
Taste disturbance (dysgeusia) 1 (4%) 1 (3%)
Muscle weakness (not due to neuropathy) 1 (4%) 1 (3%)
Neuropathy - sensory 1 (4%) 1 (3%)
Headache 1 (4%) 1 (3%)
Neuropathic pain (jaw, neuro, limb pain) 1 (4%) 1 (3%)
Dry skin 1 (4%) 1 (3%)
- NCI CTC - National Cancer Institute Common Toxicity Criteria.
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(n = 1) and nausea with vomiting (n = 1). Serious study
drug-related adverse events occurred in 3 patients: diar-
rhoea, hypertension, hand-foot skin reaction and
dehydration.
Pharmacokinetics
Steady-state pharmacokinetic parameters for telatinib
and its metabolite BAY 60-8246 on day 14 of cycle 1
are summarized in Table 3. Maximum telatinib concen-
trations were typically observed less than 3 hours post-
dose. No clear relationship between telatinib dose and
Cmax and AUC was apparent in the 600 mg bid to 1500
mg bid dose range (Figure 1). Furthermore, average
metabolite BAY 60-8246 Cmax and AUC values were
also comparable in the 600 mg bid to 1500 mg bid dose
range (Table 3).
Pharmacodynamics
The analysis of telatinib AUC(0-12) on day 14 of cycle 1
versus the ratio of the DCE-MRI contrast agent gadoli-
nium iAUC60 on day 14 of cycle 1 to iAUC60 at baseline
is shown in Figure 2a. The gadolinium iAUC60 ratio
decreased with increasing telatinib AUC(0-12) (regression
r
2 = 0.2637; Pearson correlation coefficient r = -0.514;
test for no correlation, H0: r =0 ,p = 0.0026).
The analysis of telatinib AUC(0-12) on day 14 of cycle
1v e r s u st h er a t i oo fs V E G F R - 2i np l a s m ao nd a y1 4o f
cycle 1 to sVEGFR-2 at baseline is shown in Figure 2b.
The ratio of sVEGFR-2 decreased with increasing telati-
nib AUC(0-12), i. e. essentially in an exposure-dependent
manner (r
2 = 0.2241; r = -0.473; H0: r =0 ,p = 0.0035).
In order to correlate biomarker changes to the clinical
outcome, the relative changes between cycle 1, day 14
and baseline for VEGF, bFGF, tumour blood flow and
tumour vessel permeability as measured by DCE-MRI
(r
2 = 0.0025, r =0 . 0 5 0 ,p = 0.7769; Figure 2d), and dia-
stolic blood pressure were correlated to the best tumour
shrinkage reached during therapy. The measured bio-
markers were not predictive for the clinical outcome.
However, the relative change between cycle 1, day 14
Table 3 Geometric mean (% coefficient of variation) of
telatinib and BAY 60-8246 pharmacokinetic parameters
on day 14 of cycle 1
Parameter Telatinib dose
600 mg bid
(n = 6)
900 mg bid
(n = 27)
1200 mg bid (n = 2)
1500 mg bid (n = 4)
(n = 6)
Telatinib
Cmax (mg/l) 0.825 (93%) 0.899 (91%)
b 1.467 (33%)
Tmax (h)
a 2.3 [1.1 - 4] 2.6 [0.5 - 8]
b 2.5 [0.67 - 4.1]
AUC(0-tn) (mg·h/l) 5.779 (71%) 5.547 (80%)
b 9.244 (31%)
AUC(0-12) (mg·h/l) 5.779 (71%) 5.761 (82%)
b 9.800 (33%)
Half-life (h) 8.2 (47%) 6.8 (47%)
c 8.1 (71%)
BAY 60-8246
Cmax (mg/l) 0.101 (203%) 0.095 (120%) 0.207 (85%)
Tmax (h)
a 2.3 [0.6 - 4] 3.2 [0.5 - 12.2] 2.6 [0.5 - 4.1]
AUC(0-tn) (mg·h/l) 0.826 (181%) 0.634 (101%) 1.499 (93%)
AUC(0-12) (mg·h/l) 0.826 (182%) 0.636 (101%)
d 1.595 (92%)
Half-life (h) 6.2 (14%)
d 6.5 (48%)
e 7.8 (38%)
b
-A U C (0-12) - area under the plasma concentration versus time curve from time
0 to 12 hours
-A U C (0-tn) - area under the plasma concentration versus time curve from time
0 to last data point
-B i d-bis in die, twice daily
-C max - maximum plasma concentration
-T max - time to reach maximum plasma concentration.
a Median [range]
b Sample size reduced by 1
c Sample size reduced by 3
d Sample size reduced by 2
e Sample size reduced by 5.
Figure 1 Pharmakinetics. Individual (open circles) and geometric mean (horizontal line) telatinib Cmax and AUC(0-12) on day 14 of cycle 1.
Geometric mean for the combined 1200 mg plus 1500 mg dose levels is shown with 1500 mg data.
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showed a tendency for correlation (r
2 = 0.2068, r =
0.455, p = 0.0102; Figure 2c). A decrease in tumour
blood flow as measured by DCE-MRI was shown in the
majority of patients (Figure 2e).
Efficacy
Tumour shrinkage at any point in time during treatment
was observed in 41% of the patients (Figure 3a) and more
than half had stable disease as best response (Table 4).
The median progression free survival was 77 days (2 to
Figure 2 Biomarkers, PK/PD. Analysis of telatinib AUC(0-12) on day
14 of cycle 1 versus the ratio of the initial 60 second area under the
gadolinium curve (iAUC60) on day 14 of cycle 1 to the iAUC60 at
baseline [A] and versus the ratio of sVEGFR-2 in plasma on day 14
of cycle 1 to sVEGFR-2 at baseline [B]; correlation of ratio of sVEGFR-
2 in plasma on day 14 of cycle 1 to sVEGFR-2 at baseline to best %
change from screening in sum of longest tumor diameters [C];
correlation of ratio of the DCE-MRI initial 60 second area under the
gadolinium curve (iAUC60) on day 14 of cycle 1 to the iAUC60 at
baseline to best percent change from screening in sum of longest
tumor diameters [D]. Best percent change of the DCE-MRI initial 60
second area under the gadolinium curve (iAUC60) from screening
compared to day 35 or any day later during study treatment. Each
column is representing 1 patient [E].
Figure 3 Tumor efficacy. Best percent change in target lesion sum
from screening compared to day 35 or any day later during study
treatment, each column is representing 1 patient [A]. Progression
free survival (days), each column is representing 1 patient [B].
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sion free survival of > 100 days (Figure 3b).
Discussion
This analysis of 39 CRC patients enrolled in a phase I
dose escalation study with a phase II like expansion
cohort showed that telatinib administered at clinically
relevant doses of ≥ 600 mg bid was well tolerated in
this patient population. The recommended phase II
dose for the single agent therapy with telatinib of 900
mg bid continuous dosing, as defined in the all comer
dose escalation part of the study, was confirmed of
being well tolerated in these heavily pretreated CRC
patients. Hypertension was clinically manageable in
most of the patients with a standard antihypertensive
treatment. Study drug-related diarrhoea led to dose
reduction or study drug discontinuation followed by a
restart in 4 patients. The occurrence of gastrointestinal
toxicities is known for other VEGF-inhibiting com-
pounds [2,3].
The variability in pharmacokinetic parameters was con-
siderable and individual patient telatinib exposure values
were generally comparable in the dose range reported
herein. Detailed pharmacokinetic analysis results in 71
patients covering a wider dose range of 75 mg bid to
1500 mg bid was reported earlier [1].
The biomarkers assessed in this study demonstrated
the biological activity of telatinib. Most of the patients,
29 out of 36, showed a decrease of iAUC60 in the DCE-
MRI measurements indicating an anti-angiogenic effect
in tumour tissue. The angiogenic factors VEGF and
sVEGFR-2 showed effects known from other VEGF-
inhibiting compounds. Changes in the DCE-MRI and
decreases in sVEGFR-2 were correlated to telatinib
exposure. There was no correlation between the clinical
outcome and the biomarker activity, only the correlation
of sVEGFR-2 changes to the tumour shrinkage showed
some dependency.
The treatment with single-agent telatinib showed no
objective remission in patients with CRC refractory to
standard chemotherapy. This is in line with phase II
study results of single-agent sunitinib treatment in CRC
patients [4]. However, one third of the CRC patients
had a PFS of > 100 days, suggesting some clinical activ-
ity in this heavily pretreated patient population.
The profiles of all competitors are summarized in a
review [5]. Telatinib is currently in the clinical develop-
ment for Gastric carcinoma and showed promising
results in a phase II study (ref.: J Clin Oncol 28, 2010
(suppl; abstr e14575), Ko et al.).
Conclusions
The observed single agent antitumor activity of telatinib
in heavily pretreated CRC patients was limited. Pharma-
codynamic results are suggestive for the biological activ-
ity of telatinib. Further evaluation of telatinib bid in
combination with standard chemotherapy regimens in
CRC patients should be considered.
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